Send to

Choose Destination
Proteomics Clin Appl. 2007 Mar;1(3):336-42. doi: 10.1002/prca.200600718.

Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer.

Author information

Institute of Immunology, People's Liberation Army, The Third Military Medical University, Chongqing, China; Department of General Surgery, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing, China.


Patients with cancer frequently develop autoantibodies. The identification of tumor autoantigens may have utility in early cancer diagnosis and immunotherapy. In this study, we used serological proteomics analysis (SERPA) to identify tumor proteins that elicit humoral response in colorectal cancer (CRC). The CRC cell line HCT116 was used as a source of proteins for 2-DE and subsequent Western blot analysis in which individual serum from patients with CRC was analyzed for autoantibodies. An autoantibody against HSP60 identified by MS was detected in 13 out of 25 patients with CRC and 1 out of 15 healthy subjects. In addition, the HSP60 expressions in tumor tissues collected from 40 patients with CRC were assessed by immunohistochemistry, and serum specimens from 100 patients with cancer and 30 healthy controls were screened for antibody titer to HSP60 by ELISA. The results showed that expressions of HSP60 in tumor tissue and serum antibody titer to HSP60 were significantly higher in patients with CRC than in healthy subjects. Thus, we conclude that the SERPA is an excellent assay for the identification of tumor-associated antigens and tumor markers. The detection of HSP60 may have clinical utility in CRC screening, diagnosis, and immunotherapy.


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center